Total potential Revenue $ 5.3 billioncosts $ 1.850 billionCapex $ 300 millionProject surplus $ 3.160 billionsold for $ 175 millionWhy ?
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%